

# Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

## **NB-1643**

RRID:CVCL\_5627

Type: Cell Line

### Proper Citation

RRID:CVCL\_5627

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_5627](https://web.expasy.org/cellosaurus/CVCL_5627)

**Proper Citation:** RRID:CVCL\_5627

**Description:** Cell line NB-1643 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Neuroblastoma

**Defining Citation:** [PMID:9802058](#), [PMID:9815701](#), [PMID:18724359](#), [PMID:20922763](#), [PMID:23202128](#), [PMID:28350380](#)

**Comments:** Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** NB-1643

**Synonyms:** NB1643, NB 1643

**Cross References:** BTO:BTO\_0002833, cancercellines:CVCL\_5627, Cell\_Model\_Passport:SIDM01388, Cosmic:1161994, Cosmic:1890114, DepMap:ACH-001303, GEO:GSM2371243, GEO:GSM2394390, GEO:GSM4104583, GEO:GSM4104584, GEO:GSM4104630, GEO:GSM4104631, GEO:GSM4105318, GEO:GSM4105319, GEO:GSM4105320, GEO:GSM4105321, GEO:GSM4105322, IARC\_TP53:23603, Wikidata:Q54907501

**ID:** CVCL\_5627

**Record Creation Time:** 20220427T220833+0000

**Record Last Update:** 20260913T004944+0000

---

## Ratings and Alerts

No rating or validation information has been found for NB-1643.

No alerts have been found for NB-1643.

---

## Data and Source Information

**Source:** [CelloSaurus](#)

---

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Bate-Eya LT, et al. (2024) Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma. Molecular oncology.

Modi A, et al. (2023) Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors. Cancer research, 83(20), 3462.

Heitzeneder S, et al. (2022) GPC2-CAR T??cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer cell, 40(1), 53.

Raman S, et al. (2021) A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. Cell reports. Medicine, 2(7), 100344.

Buongervino S, et al. (2021) Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. Molecular cancer therapeutics, 20(11), 2228.

Bosse KR, et al. (2017) Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer cell, 32(3), 295.